292 related articles for article (PubMed ID: 37781391)
1. Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer.
Zeller T; Münnich IA; Windisch R; Hilger P; Schewe DM; Humpe A; Kellner C
Front Immunol; 2023; 14():1240275. PubMed ID: 37781391
[TBL] [Abstract][Full Text] [Related]
2. Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages.
Zeller T; Lutz S; Münnich IA; Windisch R; Hilger P; Herold T; Tahiri N; Banck JC; Weigert O; Moosmann A; von Bergwelt-Baildon M; Flamann C; Bruns H; Wichmann C; Baumann N; Valerius T; Schewe DM; Peipp M; Rösner T; Humpe A; Kellner C
Front Immunol; 2022; 13():929339. PubMed ID: 36389667
[TBL] [Abstract][Full Text] [Related]
3. The MHC class I-LILRB1 signalling axis as a promising target in cancer therapy.
Zhao J; Zhong S; Niu X; Jiang J; Zhang R; Li Q
Scand J Immunol; 2019 Nov; 90(5):e12804. PubMed ID: 31267559
[TBL] [Abstract][Full Text] [Related]
4. Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells.
Chen H; Chen Y; Deng M; John S; Gui X; Kansagra A; Chen W; Kim J; Lewis C; Wu G; Xie J; Zhang L; Huang R; Liu X; Arase H; Huang Y; Yu H; Luo W; Xia N; Zhang N; An Z; Zhang CC
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32771992
[TBL] [Abstract][Full Text] [Related]
5. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy.
Barkal AA; Weiskopf K; Kao KS; Gordon SR; Rosental B; Yiu YY; George BM; Markovic M; Ring NG; Tsai JM; McKenna KM; Ho PY; Cheng RZ; Chen JY; Barkal LJ; Ring AM; Weissman IL; Maute RL
Nat Immunol; 2018 Jan; 19(1):76-84. PubMed ID: 29180808
[TBL] [Abstract][Full Text] [Related]
6. Expression of leukocyte immunoglobulin-like receptor subfamily B expression on immune cells in hepatocellular carcinoma.
Fan J; Li J; Han J; Zhang Y; Gu A; Song F; Duan J; Yin D; Wang L; Yi Y
Mol Immunol; 2021 Aug; 136():82-97. PubMed ID: 34098344
[TBL] [Abstract][Full Text] [Related]
7. Structures of the four Ig-like domain LILRB2 and the four-domain LILRB1 and HLA-G1 complex.
Wang Q; Song H; Cheng H; Qi J; Nam G; Tan S; Wang J; Fang M; Shi Y; Tian Z; Cao X; An Z; Yan J; Gao GF
Cell Mol Immunol; 2020 Sep; 17(9):966-975. PubMed ID: 31273318
[TBL] [Abstract][Full Text] [Related]
8. LILRB1 Blockade Enhances Bispecific T Cell Engager Antibody-Induced Tumor Cell Killing by Effector CD8
Kim A; Han CJ; Driver I; Olow A; Sewell AK; Zhang Z; Ouyang W; Egen JG; Yu X
J Immunol; 2019 Aug; 203(4):1076-1087. PubMed ID: 31253728
[TBL] [Abstract][Full Text] [Related]
9. Interaction of the LILRB1 inhibitory receptor with HLA class Ia dimers.
Baía D; Pou J; Jones D; Mandelboim O; Trowsdale J; Muntasell A; López-Botet M
Eur J Immunol; 2016 Jul; 46(7):1681-90. PubMed ID: 27109306
[TBL] [Abstract][Full Text] [Related]
10. Effect of cytomegalovirus infection and leukocyte immunoglobulin like receptor B1 polymorphisms on receptor expression in peripheral blood mononuclear cells.
Cadena-Mota S; Monsiváis-Urenda A; Salgado-Bustamante M; Monjarás-Ávila C; Bernal-Silva S; Aranda-Romo S; Noyola DE
Microbiol Immunol; 2018 Dec; 62(12):755-762. PubMed ID: 30461037
[TBL] [Abstract][Full Text] [Related]
11. The MHC-E peptide ligands for checkpoint CD94/NKG2A are governed by inflammatory signals, whereas LILRB1/2 receptors are peptide indifferent.
Middelburg J; Ghaffari S; Schoufour TAW; Sluijter M; Schaap G; Göynük B; Sala BM; Al-Tamimi L; Scheeren F; Franken KLMC; Akkermans JJLL; Cabukusta B; Joosten SA; Derksen I; Neefjes J; van der Burg SH; Achour A; Wijdeven RHM; Weidanz J; van Hall T
Cell Rep; 2023 Dec; 42(12):113516. PubMed ID: 38048225
[TBL] [Abstract][Full Text] [Related]
12. Innate Immune Checkpoint Inhibitors: The Next Breakthrough in Medical Oncology?
Lentz RW; Colton MD; Mitra SS; Messersmith WA
Mol Cancer Ther; 2021 Jun; 20(6):961-974. PubMed ID: 33850005
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for RIFIN-mediated activation of LILRB1 in malaria.
Harrison TE; Mørch AM; Felce JH; Sakoguchi A; Reid AJ; Arase H; Dustin ML; Higgins MK
Nature; 2020 Nov; 587(7833):309-312. PubMed ID: 32650338
[TBL] [Abstract][Full Text] [Related]
14. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
[TBL] [Abstract][Full Text] [Related]
15. Natural killer cell profiles in recurrent pregnancy loss: Increased expression and positive associations with TACTILE and LILRB1.
Habets DHJ; Schlütter A; van Kuijk SMJ; Spaanderman MEA; Al-Nasiry S; Wieten L
Am J Reprod Immunol; 2022 Nov; 88(5):e13612. PubMed ID: 36004818
[TBL] [Abstract][Full Text] [Related]
16. LILRB1 polymorphisms influence posttransplant HCMV susceptibility and ligand interactions.
Yu K; Davidson CL; Wójtowicz A; Lisboa L; Wang T; Airo AM; Villard J; Buratto J; Sandalova T; Achour A; Humar A; Boggian K; Cusini A; van Delden C; Egli A; Manuel O; Mueller N; Bochud PY; ; Burshtyn DN
J Clin Invest; 2018 Apr; 128(4):1523-1537. PubMed ID: 29528338
[TBL] [Abstract][Full Text] [Related]
17. Leukocyte immunoglobulin-like receptor subfamily B member 1 potentially acts as a diagnostic and prognostic target in certain subtypes of adenocarcinoma.
Cheng J; Gao X; Zhang X; Guo H; Chen S; Gou X
Med Hypotheses; 2020 Nov; 144():109863. PubMed ID: 32534335
[TBL] [Abstract][Full Text] [Related]
18. LILRB1
Xu X; Yin S; Wang Y; Zhu Q; Zheng G; Lu Y; Li T; Zhu C
Int Immunopharmacol; 2023 Jun; 119():110162. PubMed ID: 37075669
[TBL] [Abstract][Full Text] [Related]
19. HLA class I molecules regulate IFN-gamma production induced in NK cells by target cells, viral products, or immature dendritic cells through the inhibitory receptor ILT2/CD85j.
Morel E; Bellón T
J Immunol; 2008 Aug; 181(4):2368-81. PubMed ID: 18684926
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of iNKT Cells by the HLA-G-ILT2 Checkpoint and Poor Stimulation by HLA-G-Expressing Tolerogenic DC.
Wu CL; Caumartin J; Amodio G; Anna F; Loustau M; Gregori S; Langlade-Demoyen P; LeMaoult J
Front Immunol; 2020; 11():608614. PubMed ID: 33505397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
